JP5541926B2 - 眼薬物送達用の新規生体材料ならびにその製造および使用方法 - Google Patents

眼薬物送達用の新規生体材料ならびにその製造および使用方法 Download PDF

Info

Publication number
JP5541926B2
JP5541926B2 JP2009548305A JP2009548305A JP5541926B2 JP 5541926 B2 JP5541926 B2 JP 5541926B2 JP 2009548305 A JP2009548305 A JP 2009548305A JP 2009548305 A JP2009548305 A JP 2009548305A JP 5541926 B2 JP5541926 B2 JP 5541926B2
Authority
JP
Japan
Prior art keywords
chitosan
composition
modified
treated
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009548305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516814A5 (enExample
JP2010516814A (ja
Inventor
ロナルド・イー・ユテヒト
カイア・エル・クロスター
テレーズ・エム・ダウニー
バーバラ・アール・ハバラー
パトリック・ディ・ユーソ
ジェイムズ・エヌ・チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2010516814A publication Critical patent/JP2010516814A/ja
Publication of JP2010516814A5 publication Critical patent/JP2010516814A5/ja
Application granted granted Critical
Publication of JP5541926B2 publication Critical patent/JP5541926B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Birds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009548305A 2007-01-31 2008-01-31 眼薬物送達用の新規生体材料ならびにその製造および使用方法 Expired - Fee Related JP5541926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88755907P 2007-01-31 2007-01-31
US60/887,559 2007-01-31
PCT/US2008/001301 WO2008094659A2 (en) 2007-01-31 2008-01-31 Novel biomaterials for ocular drug delivery and a method for making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014044210A Division JP2014129408A (ja) 2007-01-31 2014-03-06 眼薬物送達用の新規生体材料ならびにその製造および使用方法

Publications (3)

Publication Number Publication Date
JP2010516814A JP2010516814A (ja) 2010-05-20
JP2010516814A5 JP2010516814A5 (enExample) 2011-03-24
JP5541926B2 true JP5541926B2 (ja) 2014-07-09

Family

ID=39409833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548305A Expired - Fee Related JP5541926B2 (ja) 2007-01-31 2008-01-31 眼薬物送達用の新規生体材料ならびにその製造および使用方法
JP2014044210A Pending JP2014129408A (ja) 2007-01-31 2014-03-06 眼薬物送達用の新規生体材料ならびにその製造および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014044210A Pending JP2014129408A (ja) 2007-01-31 2014-03-06 眼薬物送達用の新規生体材料ならびにその製造および使用方法

Country Status (9)

Country Link
US (5) US9855337B2 (enExample)
EP (2) EP2425816A3 (enExample)
JP (2) JP5541926B2 (enExample)
KR (1) KR20090108723A (enExample)
AU (1) AU2008211083B2 (enExample)
BR (1) BRPI0807065A2 (enExample)
CA (1) CA2676919C (enExample)
MX (1) MX2009008170A (enExample)
WO (2) WO2008094659A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653390C (en) 2006-06-02 2014-07-08 Hawaii Chitopure, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
BRPI0807065A2 (pt) * 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
ES2552842T3 (es) 2007-02-19 2015-12-02 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
US20100009009A1 (en) * 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
CN101780105B (zh) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 小牛血去蛋白提取物的滴眼液
US20100233101A1 (en) 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
US9271925B2 (en) 2013-03-11 2016-03-01 Bioinspire Technologies, Inc. Multi-layer biodegradable device having adjustable drug release profile
WO2011035020A1 (en) 2009-09-18 2011-03-24 Bioinspire Technologies, Inc. Free-standing biodegradable patch
CN101695583B (zh) * 2009-10-29 2012-12-26 中国人民解放军第三军医大学第一附属医院 一种用于组织修复的颗粒状生物材料及其制备方法
KR101883797B1 (ko) 2010-04-15 2018-08-30 마린 폴리머 테크놀로지스, 인코퍼레이션. 폴리-ｎ-아세틸글루코사민 나노섬유의 항-세균성 용도
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法
AU2012217922B2 (en) * 2011-02-14 2017-05-04 Allergan, Inc. Ester derivatives of bimatoprost compositions and methods
EP3501284A1 (en) 2011-04-15 2019-06-26 Marine Polymer Technologies, Inc. Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers
US9962401B2 (en) * 2011-09-27 2018-05-08 Purdue Research Foundation Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles
SG11201400815TA (en) * 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
US9956291B2 (en) * 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
AU2013353985B2 (en) * 2012-12-07 2017-07-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
TWI485189B (zh) 2012-12-28 2015-05-21 Ind Tech Res Inst 固體製劑及其製造方法
EP3003026B1 (en) 2013-03-14 2019-07-17 Tricol Biomedical, Inc. Biocompatible and bioabsorbable derivatized chitosan compositions
GB201309788D0 (en) * 2013-05-31 2013-07-17 Medtrade Products Ltd Process for the removal of contamination from a raw material
SG11201608402WA (en) 2014-05-07 2016-11-29 Croma Pharma Ges M B H Aqueous ophthalmic solution and method for treating dry eye syndrome
US10449272B2 (en) 2015-10-16 2019-10-22 Industrial Technology Research Institute Hydrogel composition and method for using the same
JP2018532753A (ja) 2015-10-30 2018-11-08 クロマ−ファーマ ゲゼルシャフト エム．ベー．ハー． 滅菌水性点眼液の治療的使用
CA3001634C (en) 2015-10-30 2023-05-23 Croma-Pharma Gesellschaft M.B.H. Therapeutic use of a sterile aqueous ophthalmic solution
US9833469B2 (en) * 2015-12-28 2017-12-05 Alumend, Llc Compositions and methods to affect skin irritation
PT3500255T (pt) 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
CA3020197C (en) 2017-09-01 2024-06-04 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
CN110343263A (zh) * 2018-04-02 2019-10-18 中国海洋大学 一种基于氢氧化钾和低温溶解壳聚糖的方法
WO2020146353A1 (en) 2019-01-08 2020-07-16 Alumend, Llc Topical compositions containing low molecular weight chitosan derivatives
CN114761544A (zh) 2019-07-26 2022-07-15 潘多姆科技私人有限公司 经生物工程化的调配物、其制备方法和实施方案
KR102119693B1 (ko) * 2019-10-31 2020-06-05 경희대학교 산학협력단 숙신화 콜라겐-피브리노겐 하이드로겔의 제조방법
EP4125749A4 (en) * 2020-04-03 2024-05-08 BioTissue Holdings Inc. METHOD OF USING UMBILICAL CORD PRODUCTS FOR THE TREATMENT OF OCULAR SURFACE DISEASES
KR20230150840A (ko) 2021-02-24 2023-10-31 오큘라 테라퓨틱스, 인코포레이티드 소관내 데포 삽입 디바이스
CN113440643B (zh) * 2021-06-10 2022-04-29 武汉大学 一种可吸收外科材料的表面抗菌处理方法
CN113881070B (zh) * 2021-11-09 2022-11-15 中北大学 具有光-应力双重响应的碳量子点/壳聚糖衍生物水凝胶的制备方法及应用
WO2025090805A1 (en) * 2023-10-25 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial irrigation solutions for endourological procedures

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8418891A (en) * 1990-07-26 1992-02-18 Monsanto Company Novel polyamines and method for preparation thereof
FR2707878A1 (fr) * 1993-07-21 1995-01-27 Imedex Nouvelles compositions adhésives à usage chirurgical.
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
US6015474A (en) 1997-06-20 2000-01-18 Protein Polymer Technologies Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants
US6200595B1 (en) 1998-04-24 2001-03-13 Kuraray Co., Ltd. Medical adhesive
JP2000288079A (ja) 1999-04-07 2000-10-17 Toyobo Co Ltd 生体組織用接着剤
JP2003503367A (ja) * 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
US6310188B1 (en) 2000-01-24 2001-10-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for producing chitin or chitosan
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US6756363B1 (en) * 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
ATA13842001A (de) * 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
ATE506079T1 (de) * 2003-11-05 2011-05-15 Photobiomed Corp Verbindungsgewebe und vernetzungsproteine mit naphthalimid-verbindungen
ES2609105T3 (es) * 2004-05-20 2017-04-18 Mentor Worldwide Llc Método de enlance covalente de ácido hialurónico y quitosano
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
EP1809237B1 (en) * 2004-11-09 2008-12-31 Novagali Pharma SA Ophthalmic oil-in-water type emulsion with stable positive zeta potential
GB0615834D0 (en) * 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
BRPI0807065A2 (pt) * 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos

Also Published As

Publication number Publication date
EP2114370B1 (en) 2012-10-03
US9855337B2 (en) 2018-01-02
MX2009008170A (es) 2009-08-12
US20160175449A1 (en) 2016-06-23
WO2008094675A2 (en) 2008-08-07
US8252771B2 (en) 2012-08-28
JP2010516814A (ja) 2010-05-20
US9884121B2 (en) 2018-02-06
US20180344859A1 (en) 2018-12-06
EP2425816A2 (en) 2012-03-07
AU2008211083A1 (en) 2008-08-07
EP2425816A3 (en) 2014-04-30
CA2676919C (en) 2013-01-29
EP2114370A2 (en) 2009-11-11
US20180344858A1 (en) 2018-12-06
CA2676919A1 (en) 2008-08-07
WO2008094675A3 (en) 2009-11-26
US20080207561A1 (en) 2008-08-28
KR20090108723A (ko) 2009-10-16
WO2008094659A2 (en) 2008-08-07
JP2014129408A (ja) 2014-07-10
WO2008094659A3 (en) 2009-05-14
AU2008211083B2 (en) 2013-08-01
US20080200948A1 (en) 2008-08-21
BRPI0807065A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
JP5541926B2 (ja) 眼薬物送達用の新規生体材料ならびにその製造および使用方法
JP6986758B2 (ja) デンドリマー−生体接着性ポリマーヒドロゲルナノ接着剤およびその使用
US8961501B2 (en) Method for applying flowable hydrogels to a cornea
Su et al. Recent progress in using biomaterials as vitreous substitutes
US20080187568A1 (en) Polymerization with precipitation of proteins for elution in physiological solution
ES2392964T3 (es) Biomateriales novedosos, su preparación y uso
US20120231072A1 (en) Thermo-responsive hydrogel compositions
JP7148987B2 (ja) 眼乾燥症候群および他の外傷を受けた非角化上皮表面を処置する組成物および方法
CN104428014A (zh) 针对视网膜脱离的生物相容性水凝胶治疗
Das et al. The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle
US9592251B2 (en) Multi-vinylsulfone containing molecule
Sha et al. In situ gels: The next new frontier in ophthalmic drug delivery system
Goostrey Preactivated thiomer mucoadhesive micelles for anterior ophthalmic drug delivery
CN115192578B (zh) 一种载槲皮素和尼达尼布混合胶束的制备
Yu Engineering Ocular Drug Delivery System for Posterior Eye Diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140502

R150 Certificate of patent or registration of utility model

Ref document number: 5541926

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees